title: Progress in chemotherapy of non-small cell lung cancer.
abstract: We reviewed the results in the literature on chemotherapy with cisplatin and/or other new agents such as etoposide and vindesine in the treatment of non-small cell lung cancer. Associations of cisplatin with vindesine or etoposide have been overall superior to combinations of older cytostatic agents. These combinations result in an average of 30-40% objective response rate with 5% complete responses. High doses of cisplatin seem to be associated with optimal results. Vinblastine, vincristine, bleomycin, methyl-GAG and dihydrogalactitol appear to be promising in combination with cisplatin.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003961:Dianhydrogalactitol / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D011897:Random Allocation; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014751:Vindesine
chemical_list: D001761:Bleomycin; D003961:Dianhydrogalactitol; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D014751:Vindesine